Figure 5.

ADV.mEnd treatment reduces tumor growth of preestablished tumors and prevents formation of lung metastases. LLC cells (1 × 10⁵) were injected s.c. into nude mice. Virus treatment by tail vein injection was given at day 7 (mean total volume, 47 mm³). (A) At 6 days after virus injection, the tumors in the endostatin group (□; nine mice) were already significantly smaller than the controls (●; seven mice). At day 26, the total volume reduction was 78% for the treatment group vs. controls (P = 0.041). ∗, Statistically significant at the P = 0.05 level by unpaired Student's t test. Overall index of tumor size, median ATTV: ADV.mEnd, 96 mm³; ADV.DL312, 208 mm³. P = 0.05 (Wilcoxon rank sum test). (B) None of the ADV.mEnd-treated mice had lung micrometastases as opposed to 100% of the ADV.DL312-treated controls who did (P = 0.0001, Fisher's exact test).